Management of ASCUS with Negative HPV in Women >30 Years
For women over 30 with ASCUS and negative high-risk HPV testing, repeat co-testing (Pap and HPV) in 3 years is recommended.
Rationale and Evidence Base
The management of HPV-negative ASCUS has evolved based on risk stratification data. Initially, 2012 guidelines suggested 5-year follow-up based on early Kaiser Permanente Northern California (KPNC) cohort data showing similar risk to negative co-testing 1. However, updated KPNC data with larger sample sizes demonstrated that the 5-year risk of CIN3+ after HPV-negative ASCUS (0.48%) was significantly higher than after negative co-testing (0.11%, P<0.0001) but closer to the risk after a negative Pap test alone (0.31%) 1. This finding prompted the change to 3-year follow-up rather than 5 years.
The most recent guidelines from multiple sources consistently recommend:
- Return for co-testing at 3 years 2, 3
- HPV-negative ASCUS should be regarded as negative for the purpose of routine screening intervals 3
- This result does NOT meet criteria for exiting screening at age 65 1
Key Clinical Points
Why 3 Years Instead of 5?
The absolute risk data is critical here. Research from Kaiser Permanente showed that among 17,191 women with HPV-negative ASCUS 4:
- 5-year CIN3+ risk: 0.48%
- 5-year cancer risk: 0.043%
While these risks are low, they exceed the threshold for negative co-testing, making 3-year surveillance more appropriate than 5-year intervals.
Important Caveats
Age-specific considerations: The cancer risk in HPV-negative ASCUS is disproportionately elevated in older women, particularly those approaching age 65. KPNC data showed that although dysplasia risk remains low, cancer risk is unexpectedly high in this demographic 1. Therefore, women reaching age 65 with an HPV-negative ASCUS result should continue surveillance with repeat testing at 3 years until they achieve 2 consecutive negative co-tests or 3 consecutive negative Pap tests 1.
Alternative Management (When Co-testing Unavailable)
If co-testing is not feasible, repeat Pap testing alone at 12 months is acceptable 5. However, this is considered a second-line approach when HPV testing resources are limited.
What NOT to Do
- Do not perform immediate colposcopy - The current risk of CIN3+ after ASCUS is below the threshold for colposcopy 1
- Do not use HPV 16/18 genotyping - Results do not alter management for ASCUS patients 1
- Do not extend to 5-year intervals - This was the initial 2012 recommendation but was revised based on updated risk data 1
Clinical Algorithm
For women >30 with ASCUS/HPV-negative:
- Reassure patient - Risk of high-grade disease is very low (0.48% over 5 years)
- Schedule co-testing in 3 years (Pap + HPV)
- If approaching age 65: Continue surveillance beyond age 65 until achieving adequate negative screening history
- Document clearly that this result counts as "negative" for routine screening purposes but requires 3-year (not 5-year) follow-up
This approach balances the low but non-negligible risk of disease progression against the burden of excessive surveillance, optimizing both patient safety and resource utilization.